{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:38:43Z","timestamp":1790393923953,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T00:00:00Z","timestamp":1592006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T00:00:00Z","timestamp":1592006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["16ck0106084h0003"],"award-info":[{"award-number":["16ck0106084h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s10147-020-01721-x","type":"journal-article","created":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T16:02:33Z","timestamp":1592064153000},"page":"1835-1843","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic\/breast\/ovarian\/prostate cancer or personal history of breast\/ovarian\/prostate cancer (FABRIC study)"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4098-5217","authenticated-orcid":false,"given":"Naohiro","family":"Okano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chigusa","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Tsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironaga","family":"Satake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobumasa","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Shioji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Asagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohichiroh","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Kashiwada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Tobimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayo","family":"Motoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,13]]},"reference":[{"key":"1721_CR1","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3748\/wjg.v23.i6.935","volume":"23","author":"H Matsubayashi","year":"2017","unstructured":"Matsubayashi H, Takaori K, Morizane C et al (2017) Familial pancreatic cancer: concept, management and issues. World J Gastroenterol 23:935\u2013948","journal-title":"World J Gastroenterol"},{"key":"1721_CR2","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1158\/0008-5472.CAN-03-3823","volume":"64","author":"AP Klein","year":"2004","unstructured":"Klein AP, Brune KA, Petersen GM et al (2004) Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64:2634\u20132638","journal-title":"Cancer Res"},{"key":"1721_CR3","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","volume":"20","author":"KP Pennington","year":"2014","unstructured":"Pennington KP, Walsh T, Harrell MI et al (2014) Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 20:764\u2013775","journal-title":"Clin Cancer Res"},{"key":"1721_CR4","doi-asserted-by":"publisher","first-page":"7521","DOI":"10.1158\/1078-0432.CCR-17-1941","volume":"23","author":"EY Zhao","year":"2017","unstructured":"Zhao EY, Shen Y, Pleasance E et al (2017) Homologous recombination deficiency and platinum-based therapy outcomes in advanced breast cancer. Clin Cancer Res 23:7521\u20137530","journal-title":"Clin Cancer Res"},{"key":"1721_CR5","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1002\/cncr.30808","volume":"123","author":"MM Pomerantz","year":"2017","unstructured":"Pomerantz MM, Spis\u00e1k S, Jia L et al (2017) The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer 123:3532\u20133539","journal-title":"Cancer"},{"key":"1721_CR6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00280-015-2788-6","volume":"76","author":"D Fogelman","year":"2015","unstructured":"Fogelman D, Sugar EA, Oliver G et al (2015) Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemother Pharmacol 76:489\u2013498","journal-title":"Cancer Chemother Pharmacol"},{"key":"1721_CR7","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/bjc.2014.418","volume":"111","author":"T Golan","year":"2014","unstructured":"Golan T, Kanji ZS, Epelbaum R et al (2014) Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 111:1132\u20131138","journal-title":"Br J Cancer"},{"key":"1721_CR8","doi-asserted-by":"publisher","first-page":"19817","DOI":"10.18632\/oncotarget.24865","volume":"9","author":"T Kondo","year":"2018","unstructured":"Kondo T, Kanai M, Kou T et al (2018) Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. Oncotarget 9:19817\u201319825","journal-title":"Oncotarget"},{"key":"1721_CR9","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817\u20131825","journal-title":"N Engl J Med"},{"key":"1721_CR10","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/cas.12501","volume":"105","author":"T Okusaka","year":"2014","unstructured":"Okusaka T, Ikeda M, Fukutomi A et al (2014) Phase II study of FOLFIRINOX for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Sci 105:1321\u20131326","journal-title":"Cancer Sci"},{"key":"1721_CR11","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1200\/JCO.2005.05.1490","volume":"24","author":"V Heinemann","year":"2006","unstructured":"Heinemann V, Quietzsch D, Gieseler F et al (2006) Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24:3946\u20133952","journal-title":"J Clin Oncol"},{"key":"1721_CR12","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1200\/JCO.2009.25.4433","volume":"28","author":"G Colucci","year":"2010","unstructured":"Colucci G, Labianca R, Di Costanzo F et al (2010) Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 28:1645\u20131651","journal-title":"J Clin Oncol"},{"key":"1721_CR13","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.1200\/JCO.2008.20.9007","volume":"27","author":"E Poplin","year":"2009","unstructured":"Poplin E, Feng Y, Berlin J et al (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the eastern cooperative oncology group. J Clin Oncol 27:3778\u20133785","journal-title":"J Clin Oncol"},{"key":"1721_CR14","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1200\/JCO.2005.06.023","volume":"23","author":"C Louvet","year":"2005","unstructured":"Louvet C, Labianca R, Hammel P et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509\u20133516","journal-title":"J Clin Oncol"},{"key":"1721_CR15","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1200\/JCO.2003.09.140","volume":"21","author":"M Tempero","year":"2003","unstructured":"Tempero M, Plunkett W, Ruiz Van Haperen V et al (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402\u20133408","journal-title":"J Clin Oncol"},{"key":"1721_CR16","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/bjc.2015.103","volume":"112","author":"S Ohkawa","year":"2015","unstructured":"Ohkawa S, Okusaka T, Isayama H et al (2015) Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer 112:1428\u20131434","journal-title":"Br J Cancer"},{"key":"1721_CR17","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1002\/cncr.23810","volume":"113","author":"HQ Xiong","year":"2008","unstructured":"Xiong HQ, Varadhachary GR, Blais JC et al (2008) Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 113:2046\u20132052","journal-title":"Cancer"},{"key":"1721_CR18","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","volume":"32","author":"H Oettle","year":"2014","unstructured":"Oettle H, Riess H, Stieler JM et al (2014) (2014) Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 32:2423\u20132429","journal-title":"J Clin Oncol"},{"key":"1721_CR19","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1200\/JCO.2016.68.5776","volume":"34","author":"S Gill","year":"2016","unstructured":"Gill S, Ko YJ, Cripps C et al (2016) PANCREOX: a randomized phase III study of fluorouracil\/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol 34:3914\u20133920","journal-title":"J Clin Oncol"},{"key":"1721_CR20","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691\u20131703","journal-title":"N Engl J Med"},{"key":"1721_CR21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00280-006-0283-9","volume":"59","author":"H Ueno","year":"2007","unstructured":"Ueno H, Okusaka T, Funakoshi A et al (2007) A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 59:447\u2013454","journal-title":"Cancer Chemother Pharmacol"},{"key":"1721_CR22","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/jjco\/hym060","volume":"37","author":"H Ueno","year":"2007","unstructured":"Ueno H, Okusaka T, Ikeda M et al (2007) Phase II study of combination chemotherapy with gemcitabine and cisplatin for patients with metastatic pancreatic cancer. Jpn J Clin Oncol 37:515\u2013520","journal-title":"Jpn J Clin Oncol"},{"key":"1721_CR23","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00280-007-0514-8","volume":"61","author":"T Okusaka","year":"2008","unstructured":"Okusaka T, Funakoshi A, Furuse J et al (2008) A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 61:615\u2013621","journal-title":"Cancer Chemother Pharmacol"},{"key":"1721_CR24","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/jjco\/hyr090","volume":"41","author":"H Ueno","year":"2011","unstructured":"Ueno H, Okusaka T, Furuse J et al (2011) Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. Jpn J Clin Oncol 41:953\u2013958","journal-title":"Jpn J Clin Oncol"},{"key":"1721_CR25","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Genetic\/Familial High-Risk Assessment: Breast and Ovarian. Version 2.2014"},{"key":"1721_CR26","doi-asserted-by":"publisher","first-page":"74227","DOI":"10.18632\/oncotarget.12490","volume":"7","author":"E Takai","year":"2016","unstructured":"Takai E, Yachida S, Shimizu K et al (2016) Germline mutations in Japanese familial pancreatic cancer patients. Oncotarget 7:74227\u201374235","journal-title":"Oncotarget"},{"key":"1721_CR27","unstructured":"NCCN Clinical Practice Guidelines in Oncology (2020). Pancreatic adenocarcinoma. Version 1. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf. Accessed 4 Jan 2020"},{"key":"1721_CR28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell N, Pajic M, Patch AM et al (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518:495\u2013501","journal-title":"Nature"},{"key":"1721_CR29","doi-asserted-by":"publisher","first-page":"6204","DOI":"10.1158\/1078-0432.CCR-18-1472","volume":"24","author":"A Sehdev","year":"2018","unstructured":"Sehdev A, Gbolahan O, Hancock BA et al (2018) Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic adenocarcinoma patients treated with FOLFIRINOX. Clin Cancer Res 24:6204\u20136211","journal-title":"Clin Cancer Res"},{"key":"1721_CR30","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M et al (2019) Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 381:317\u2013327","journal-title":"N Engl J Med"},{"key":"1721_CR31","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1200\/JCO.2014.59.7401","volume":"33","author":"S Holter","year":"2015","unstructured":"Holter S, Borgida A, Dodd A et al (2015) Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol 33:3124\u20133129","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01721-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-020-01721-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01721-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T23:47:26Z","timestamp":1623541646000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-020-01721-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,13]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1721"],"URL":"https:\/\/doi.org\/10.1007\/s10147-020-01721-x","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,13]]},"assertion":[{"value":"11 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Morizane C. received research funding from Yakult Honsha, and Eli Lilly Japan. Satake H. received honoraria from Eli Lilly Japan. Mizuno N. received research funding from Dainippon Sumitomo Pharma, MSD, ASLAN Pharmaceuticals, Incyte, and Yakult Honsha. Kanai M received from honoraria from Chugai Pharmaceutical. Shimizu S. received research funding from Yakult Honsha.Ikeda M. received honoraria from Eli Lilly Japan, and received research funding from Yakult Honsha. Okusaka T. received research funding from AstraZeneca, Chugai Pharmaceutical, Eisai, Novartis Pharma, and Bristol-Myers. Furuse J. received honoraria and research funding from Yakult Honsha, and Eli Lilly Japan. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed in accordance with the ethical standards established in the 1964 Declaration of Helsinki and its later amendments. The study was approved by the institutional review board of each study site, and all the patients provided informed consent prior to their inclusion in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}